Serial Number
88186670
Owner
Mezzion Pharma Co., Ltd.Attorney
Daniel R. MelloFiling Date
Nov 8, 2018
SHAPING THE FUTURE OF SINGLE VENTRICLE HEART DISEASE (SVHD) Trademark
Serial Number: 88186670 • Registration: 6337606
Trademark Classes
Class 41 - Education & Entertainment
Education; providing of training; entertainment; sporting and cultural activities
Class 42 - Computer & Scientific
Scientific and technological services; industrial analysis and research services
Class 44 - Medical Services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Owner Contact Info
7F, 570 Samseong-ro, Gangnam-gu
Seoul 06163 , KR
Entity Type: 99
Legal Representation
Correspondence Address
Daniel R. Mello Finnegan, Henderson, Farabow, Garrett & Dunner LLP
901 New York Avenue NW
Washington, DC 20001
United States
Trademark Details
Filing Date
November 8, 2018
Registration Date
May 4, 2021
Published for Opposition
February 16, 2021
Goods & Services
Providing websites featuring information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals and medicine, health, wellness, and cardiac health issues; Medical testing and screening services, namely, medical diagnostic testing services and medical screening for the treatment of cardiac disease and disorders, and single ventricle heart disease (SVHD), including SVHD subjects who have undergone Fontan Palliation; providing a website featuring information in the field of health and wellness; providing a website featuring medical information in the field of cardiac issues; medical testing services, namely, providing medical testing services and information in the field of the treatment of cardiac disease and disorders
Medical and pharmaceutical research for the treatment of cardiac disease and disorders; Medical and pharmaceutical research for the treatment of cardiac disease and disorders, namely, single ventricle heart disease (SVHD), including SVHD subjects who have undergone Fontan Palliation and product development services; scientific and technological research services related thereto, namely, scientific research services for the treatment of cardiac disease and disorders, namely, single ventricle heart disease (SVHD), including SVHD subjects who have undergone Fontan Palliation; Medical and pharmaceutical research for the treatment of cardiac disease and disorders, namely, single ventricle heart disease (SVHD), including SVHD subjects who have undergone Fontan Palliation; conducting clinical trials for others
Educational services, namely, seminars in the field of pharmaceuticals, medicine, health, wellbeing, and cardiac issues and distribution of course materials in connection therewith; providing a website featuring blogs in the field of pharmaceuticals, medicine, health, wellbeing, and cardiac issues
